Effectiveness of CAM Therapy: Understanding the Evidence

Rheumatic Disease Clinics of North America

Volumn 37, Issue 1, 2011, Pages 9-17

  Staud, Roland ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Complementary Medicine; Efficacy; Treatment

Indexed keywords

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANALGESIA; AYURVEDA; CHINESE MEDICINE; DIET THERAPY; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; HERBAL MEDICINE; HOMEOPATHY; HUMAN; HYPNOSIS; MAGNETOTHERAPY; MANIPULATIVE MEDICINE; MEDICAL RESEARCH; MEDITATION; MUSCULOSKELETAL PAIN; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIKI; RELAXATION TRAINING; RELIGION; REVIEW;

ANALGESIA; ANALGESICS; CHRONIC DISEASE; HERBAL MEDICINE; HUMANS; MEDICINE, CHINESE TRADITIONAL; MIND-BODY THERAPIES; MUSCULOSKELETAL DISEASES; MUSCULOSKELETAL MANIPULATIONS; NEEDS ASSESSMENT; PAIN; PLACEBO EFFECT; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 78650934154     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2010.11.009     Document Type: Review

References (58)

1. [Anon] CAM definition 2010, National Center for Complementary and Alternative Medicine, Available at:, Accessed November 17, 2010. http://nccam.nih.gov/health/whatiscam/#l.
2. Barnes P., Powell-Griner E., McFann K., et al. Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics 343, 1-20 2004, National Center for Health Statistics, Hyattsville (MD).
3. Pioro-Boisset M., Esdaile J.M., Fitzcharles M.A. Alternative medicine use in fibromyalgia syndrome. Arthritis Care Res 1996, 9(1):13-17.
4. Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ 2000, 78(2):252-257.
5. Sim J., Adams N. Systematic review of randomized controlled trials of nonpharmacological interventions for fibromyalgia. Clin J Pain 2002, 18(5):324-336.
6. Rossy L.A., Buckelew S.P., Dorr N., et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 1999, 21(2):180-191.
7. Ernst E. Complementary and alternative medicine for fibromyalgia. Fibromyalgia and other central pain syndromes 2005, 383-408. Lippincott William & Wilkins, Philadelphia. D.J. Wallace, D.J. Clauw (Eds.).
8. Mayhew E., Ernst E. Acupuncture for fibromyalgia - a systemic review of randomized clinical trials. Rheumatology 2007, 46:801-804.
9. Ernst E. Complementary treatments in rheumatic diseases. Rheum Dis Clin North Am 2008, 34(2):455-467.
10. Perry R., Terry R., Ernst E. A systematic review of homoeopathy for the treatment of fibromyalgia. Clin Rheumatol 2010, 29(5):457-464.
11. Crofford L.J., Appleton B.E. Complementary and alternative therapies for fibromyalgia. Curr Rheumatol Rep 2001, 3(2):147-156.
12. Jadad A.R., Cook D.J., Jones A., et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA 1998, 280(3):278-280.
13. [Anon] What is complementary and alternative medicine? NCCAM Publication D156 2002, National Center for Complementary and Alternative Medicine, Available at:, Accessed November 17, 2010. http://nccam.nih.gov/health/whatiscam/.
14. Singh S., Ernst E. Trick or treatment? Alternative medicine on trial 2008, Bantam Press, New York.
15. Guyatt G.H., Oxman A.D., Kunz R., et al. Going from evidence to recommendations. BMJ 2008, 336(7652):1049-1051.
16. Walach H., Falkenberg T., Fonnebo V., et al. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol 2006, 6:29.
17. Coulter I.D. Evidence summaries and synthesis: necessary but insufficient approach for determining clinical practice of integrated medicine?. Integr Cancer Ther 2006, 5(4):282-286.
18. Jonas W.B., Beckner W., Coulter I. Proposal for an integrated evaluation model for the study of whole systems health care in cancer. Integr Cancer Ther 2006, 5(4):315-319.
19. Walach H. The efficacy paradox in randomized controlled trials of CAM and elsewhere: beware of the placebo trap. J Altern Complement Med 2001, 7(3):213-218.
20. Beecher H.K. The powerful placebo. JAMA 1955, 159:1602-1606.
21. Levine J.D., Gordon N.C., Bornstein J.C., et al. Role of pain in placebo analgesia. Proc Natl Acad Sci U S A 1979, 76(7):3528-3531.
22. Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996, 64(3):535-543.
23. Petrovic P., Kalso E., Petersson K.M., et al. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002, 295(5560):1737-1740.
24. Amanzio M., Pollo A., Maggi G., et al. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 2001, 90(3):205-215.
25. Benedetti F., Amanzio M., Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995, 346(8984):1231.
26. Gracely R.H., Dubner R., Wolskee P.J., et al. Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 1983, 306(5940):264-265.
27. Levine J.D., Gordon N.C. Influence of the method of drug administration on analgesic response. Nature 1984, 312(5996):755-756.
28. Price D.D., Riley J.L., Wade J.B. Psychophysical approaches to measurement of the dimensions and stages of pain. Handbook of pain assessment 2001, 53-75. Guilford Press, New York. 2nd edition. D.C. Turk, R. Melzack (Eds.).
29. Vase L., Price D.D., Verne G.N., et al. The contribution of changes in expected pain levels and desire for relief to placebo analgesia. Psychological methods of pain control: basic science and clinical perspectives 2004, 29:207-232. IASP Press, Seattle (WA). D.D. Price, M.C. Bushnell (Eds.).
30. Vase L., Robinson M.E., Verne G.N., et al. Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005, 115(3):338-347.
31. Vase L., Robinson M.E., Verne G.N., et al. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients-an empirical investigation. Pain 2003, 105(1-2):17-25.
32. Colloca L., Benedetti F., Pollo A. Repeatability of autonomic responses to pain anticipation and pain stimulation. Eur J Pain 2006, 10(7):659-665.
33. Kaptchuk T.J. Powerful placebo: the dark side of the randomised controlled trial. Lancet 1998, 351(9117):1722-1725.
34. Hrobjartsson A. What are the main methodological problems in the estimation of placebo effects?. J Clin Epidemiol 2002, 55(5):430-435.
35. Miller F.G., Kaptchuk T.J. The power of context: reconceptualizing the placebo effect. J R Soc Med 2008, 101(5):222-225.
36. Moerman D.E., Jonas W.B. Deconstructing the placebo effect and finding the meaning response. Ann Intern Med 2002, 136(6):471-476.
37. Kaptchuk T.J., Kelley J.M., Conboy L.A., et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008, 336(7651):999-1003.
38. Cremonini F., Delgado-Aros S., Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003, 15(1):79-86.
39. Lesbros-Pantoflickova D., Michetti P., Fried M., et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20(11-12):1253-1269.
40. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12.
41. Kirsch I., Moore T.J., Scoboria A., et al. The emperor's new drugs: an analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 2002, 5. 10.1037/1522-3736.5.1.523a.
42. Walach H., Maidhof C. Is the placebo effect dependent on time?. Expectance, experience, and behavior 1999, 321-332. American Psychological Association, Washington, DC. I. Kirsch (Ed.).
43. Walach H., Sadaghiani C., Dehm C., et al. The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials-a secondary analysis. BMC Med Res Methodol 2005, 5(26):1-12.
44. Staud R., Price D.D. Importance of measuring placebo factors in complex clinical trials. Pain 2008, 138:473-474.
45. Staud R., Price D.D. Role of placebo factors in clinical trials with special focus on enrichment designs. Pain 2008, 139:479-480.
46. Thornton A., Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000, 53(2):207-216.
47. Turner E.H., Matthews A.M., Linardatos E., et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358(3):252-260.
48. McDonald C.J., Mazzuca S.A., McCabe G.P. How much of the placebo 'effect' is really statistical regression?. Stat Med 1983, 2(4):417-427.
49. Verhoef M.J., Casebeer A.L., Hilsden R.J. Assessing efficacy of complementary medicine: adding qualitative research methods to the " Gold Standard" J Altern Complement Med 2002, 8(3):275-281.
50. Ritenbaugh C., Verhoef M., Fleishman S., et al. Whole systems research: a discipline for studying complementary and alternative medicine. Altern Ther Health Med 2003, 9(4):32-36.
51. Weatherley-Jones E., Thompson E.A., Thomas K.J. The placebo-controlled trial as a test of complementary and alternative medicine: observations from research experience of individualised homeopathic treatment. Homeopathy 2004, 93(4):186-189.
52. Institute of Medicine. Need for innovative designs in research on CAM and conventional medicine. Complementary and alternative medicine in the United States. National Academic Press 2005;(4):108-28.
53. Vickers A.J., Rees R.W., Zollman C.E., et al. Acupuncture of chronic headache disorders in primary care: randomised controlled trial and economic analysis. Health Technol Assess 2004, 8(48):iii. 1-35.
54. [ANON] United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 2004, 329(7479):1381.
55. King M., Nazareth I., Lampe F., et al. Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA 2005, 293(9):1089-1099.
56. Bower P., King M., Nazareth I., et al. Patient preferences in randomised controlled trials: conceptual framework and implications for research. Soc Sci Med 2005, 61(3):685-695.
57. Johnston B.C., Mills E. n-of-1 randomized controlled trials: an opportunity for complementary and alternative medicine evaluation. J Altern Complement Med 2004, 10(6):979-984.
58. Hankey G.J. Are n-of-1 trials of any practical value to clinicians and researchers?. The lancet: treating individuals: from randomized trials to personalized medicine 2007, 231-244. Elsevier Health Sciences, Edinburgh (Scotland). P.M. Rothwell (Ed.).